Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enhancing the Natriuretic Peptide System in HFpEF
NCT05279742Phase 2Enrolling by invitation
- Start
- Nov 2022
- Primary completion
- Apr 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of M-atrial natriuretic peptide in heart failure with preserved ejection fraction (HFpEF). Started Nov 2022; status: enrolling by invitation.
02
Drugs
M-atrial natriuretic peptide
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05279742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279742.